<p>Skba Capital Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第三季度其在 DENTSPLY SIRONA Inc.（NASDAQ:XRAY - 免费报告）的股份增加了 14.3%。这家机构投资者在该季度购买了额外的 142,900 股后，持有 1,140,430 股这家医疗器械供应商的股票。DENTSPLY SIRONA 占 Skba Capital Management LLC 投资组合的约 2.0%，是其第 15 大持股。到最近报告期末，Skba Capital Management LLC 持有 DENTSPLY SIRONA 的股份占比为 0.57%，价值 14,472,000 美元。</p>
<ul>
<li>Dentsply 股票正在重新定价</li>
</ul>
<p>其他一些对冲基金最近也增加或减少了在 XRAY 的持股。AQR Capital Management LLC 在第二季度将其在 DENTSPLY SIRONA 的持股增加了 109.8%。AQR Capital Management LLC 目前持有 13,316,771 股这家医疗器械供应商的股票，价值 211,470,000 美元，此前在上个季度购买了额外的 6,970,086 股。挪威银行在第二季度收购了 DENTSPLY SIRONA 的新股份，价值约 39,700,000 美元。高盛集团在第一季度将其在 DENTSPLY SIRONA 的持股增加了 827.3%。高盛集团目前持有 2,434,925 股这家医疗器械供应商的股票，价值 36,378,000 美元，此前在上个季度购买了额外的 2,172,343 股。Brickwood Asset Management LLP 在第三季度将其在 DENTSPLY SIRONA 的持股增加了 5,515.8%。Brickwood Asset Management LLP 目前持有 1,524,074 股这家医疗器械供应商的股票，价值 19,340,000 美元，此前在上个季度购买了额外的 1,496,935 股。最后，先锋集团在第三季度将其在 DENTSPLY SIRONA 的持股增加了 4.1%。先锋集团目前持有 22,006,576 股这家医疗器械供应商的股票，价值 279,263,000 美元，此前在此期间购买了额外的 869,566 股。95.70% 的股票由对冲基金和其他机构投资者持有。</p>
<p>获取 <strong>DENTSPLY SIRONA</strong> 的提醒：</p>
<h2>华尔街分析师的看法</h2>
<p>一些分析师最近对 XRAY 股票发表了评论。巴克莱在 12 月 8 日的研究报告中开始覆盖 DENTSPLY SIRONA。他们给予该公司的 &#34;减持&#34; 评级，目标价为 12.00 美元。瑞穗证券在周一将 DENTSPLY SIRONA 的目标价从 14.00 美元上调至 16.00 美元，并给予该股票 &#34;中性&#34; 评级。美国银行在 2 月 19 日的报告中将 DENTSPLY SIRONA 的评级从 &#34;中性&#34; 上调至 &#34;买入&#34;，并将其目标价从 13.00 美元上调至 17.00 美元。Zacks Research 在周一的研究报告中将 DENTSPLY SIRONA 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。最后，瑞银集团在 2 月 3 日的研究报告中将 DENTSPLY SIRONA 的目标价从 17.00 美元下调至 16.00 美元，并给予该公司 &#34;买入&#34; 评级。三位研究分析师对该股票给予了买入评级，十位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，DENTSPLY SIRONA 的平均评级为 &#34;持有&#34;，平均目标价为 14.42 美元。</p>
<p><strong>查看我们对 XRAY 的最新分析</strong></p>
<h2>DENTSPLY SIRONA 的内部交易</h2>
<p>在相关消息中，董事 Gregory T. Lucier 在 12 月 8 日的交易中出售了 82,200 股该公司的股票。该股票以平均价格 11.14 美元出售，总交易额为 915,708.00 美元。此次出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。内部人士持有该公司 0.52% 的股票。</p>
<h2>DENTSPLY SIRONA 股票表现</h2>
<p>DENTSPLY SIRONA 股票在周三开盘价为 13.30 美元。该公司的市值为 26.6 亿美元，市盈率为 -4.43，市盈增长比率为 1.68，贝塔值为 0.97。该公司的速动比率为 1.03，流动比率为 1.51，债务股本比率为 1.50。DENTSPLY SIRONA Inc. 的 52 周低点为 9.85 美元，52 周高点为 17.18 美元。该公司的 50 日简单移动平均线为 12.52 美元，200 日简单移动平均线为 12.47 美元。</p>
<p>DENTSPLY SIRONA (NASDAQ:XRAY - 获取免费报告) 最近在 2 月 26 日宣布了其财报。这家医疗器械供应商报告本季度每股收益为 0.27 美元，低于市场共识预期的 0.28 美元（差额为 0.01 美元）。DENTSPLY SIRONA 的股本回报率为 18.85%，净利润率为 -16.25%。该公司本季度的收入为 9.61 亿美元，而分析师预期为 9.264 亿美元。去年同期，该公司的每股收益为 0.26 美元。该公司的季度收入较去年同期增长了 6.2%。DENTSPLY SIRONA 已将其 2026 财年的指导目标设定为每股收益 1.400-1.500 美元。股票分析师预测 DENTSPLY SIRONA Inc. 今年的每股收益将达到 1.84 美元。</p>
<h2>DENTSPLY SIRONA 宣布分红</h2>
<p>该公司最近还披露了季度分红，已于 1 月 9 日（星期五）支付。12 月 26 日的登记投资者获得了 0.16 美元的分红。这代表着每年 0.64 美元的分红和 4.8% 的分红收益率。除息日为 12 月 26 日。DENTSPLY SIRONA 目前的派息比率为 -21.33%。</p>
<h2>影响 DENTSPLY SIRONA 的关键故事</h2>
<p>以下是本周影响 DENTSPLY SIRONA 的关键新闻故事：</p>
<ul>
<li>积极情绪：董事买入：Gregory T. Lucier 于 3 月 3 日购买了 22,445 股（约 $14.03），在 3 月 2 日购买了 27,555 股（约 $14.24），使其报告持股增至约 50,000 股——这是一种强烈的内部信心投票，通常会支持股价。董事购买 - InsiderTrades</li>
<li>积极情绪：Barrington Research 将其目标价上调至 $17，并维持 &#34;跑赢大盘&#34; 的评级——相对于当前水平的显著上行预期，可能吸引买入兴趣。Barrington Research 目标价上调</li>
<li>积极情绪：Zacks 将 XRAY 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;，去除了强烈的负面标签，支持市场情绪改善。Zacks 上调</li>
<li>中性情绪：瑞穗将其目标价上调至 $16，但维持 &#34;中性&#34; 评级——这一目标价的提升有助于情绪，但不变的评级抑制了短期买入压力。瑞穗目标价更新</li>
<li>中性情绪：投资者接入：管理层将在 3 月 10 日的 Leerink Partners 全球医疗会议上进行演讲——如果管理层提供增量指导或信息，这可能成为短期催化剂。会议通知</li>
<li>中性情绪：近期报告中的空头头寸数据似乎异常（报告显示零 / NaN 变化）——将这些空头头寸更新视为报告噪音，而非真实的空头挤压信号。</li>
<li>消极情绪：近期基本面仍显示出摩擦：第四季度报告（2 月 26 日）包括轻微的每股收益失误（$0.27 对 $0.28）和负净利润率，提醒我们盈利能力和利润率恢复仍然是长期上行的关键风险。MarketBeat XRAY 摘要</li>
</ul>
<h2>DENTSPLY SIRONA 概况</h2>
<p>（免费报告）</p>
<p>Dentsply Sirona Inc NASDAQ: XRAY 是一家领先的全球专业牙科产品和技术制造商。该公司于 2016 年 2 月通过 Dentsply International 和 Sirona Dental Systems 的合并成立，汇聚了在牙科护理领域的悠久创新传统。总部位于北卡罗来纳州夏洛特，Dentsply Sirona 开发和销售全面的牙科耗材、实验室产品以及先进的成像和 CAD/CAM 系统。</p>
<p>公司的产品组合涵盖预防性、修复性、正畸、根管治疗和外科护理。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 DENTSPLY SIRONA</li>
<li>新发现的富铜 &#34;克拉肯&#34; 区域</li>
<li>美国的 1776 再次上演</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>白银的挤压正在收紧 - 机会正在形成</li>
<li>特朗普的新行政命令 - 退休账户即将发生重大变化</li>
</ul>
<p><strong>想看看其他对 XRAY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 DENTSPLY SIRONA Inc.（NASDAQ:XRAY - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WFJBWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WFJBWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 DENTSPLY SIRONA 吗？</h2>
<p>在考虑 DENTSPLY SIRONA 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 DENTSPLY SIRONA 并不在名单上。</p>
<p>虽然 DENTSPLY SIRONA 目前在分析师中获得 &#34;持有&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

美国医药设备 ETF - iShares

登士柏西诺德

医疗业 ETF - SPDR

标普健康医疗设备 ETF - SPDR

<p>Skba Capital Management LLC 在第三季度将其在 DENTSPLY SIRONA Inc. (NASDAQ:XRAY) 的持股增加了 14.3%，在购买了 142,900 股后，持有 1,140,430 股。该股票占 Skba 投资组合的 2.0%。其他对冲基金也调整了其持股，AQR Capital Management 的持股增加了 109.8%。分析师对 XRAY 的评级褒贬不一，平均目标价为 14.42 美元。DENTSPLY SIRONA 的股票开盘价为 13.30 美元，市值为 26.6 亿美元，52 周区间为 9.85 至 17.18 美元</p>

<p>Skba Capital Management LLC grew its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) by 14.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,140,430 shares of the medical instruments supplier's stock after purchasing an additional 142,900 shares during the quarter. DENTSPLY SIRONA makes up about 2.0% of Skba Capital Management LLC's portfolio, making the stock its 15th biggest holding. Skba Capital Management LLC owned 0.57% of DENTSPLY SIRONA worth $14,472,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Skba Capital Management LLC 在最近向证券交易委员会（SEC）提交的文件中表示，在第三季度其在 DENTSPLY SIRONA Inc.（NASDAQ:XRAY - 免费报告）的股份增加了 14.3%。这家机构投资者在该季度购买了额外的 142,900 股后，持有 1,140,430 股这家医疗器械供应商的股票。DENTSPLY SIRONA 占 Skba Capital Management LLC 投资组合的约 2.0%，是其第 15 大持股。到最近报告期末，Skba Capital Management LLC 持有 DENTSPLY SIRONA 的股份占比为 0.57%，价值 14,472,000 美元。</p>
</div><ul>
<li>Dentsply Stock is Repricing Itself</li>
</ul>
<div class="lb-trans"><ul>
<li>Dentsply 股票正在重新定价</li>
</ul>
</div><p>A number of other hedge funds have also recently added to or reduced their stakes in XRAY. AQR Capital Management LLC increased its holdings in DENTSPLY SIRONA by 109.8% in the second quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier's stock valued at $211,470,000 after buying an additional 6,970,086 shares in the last quarter. Norges Bank acquired a new stake in shares of DENTSPLY SIRONA during the 2nd quarter valued at about $39,700,000. Goldman Sachs Group Inc. increased its stake in shares of DENTSPLY SIRONA by 827.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock valued at $36,378,000 after purchasing an additional 2,172,343 shares in the last quarter. Brickwood Asset Management LLP increased its stake in shares of DENTSPLY SIRONA by 5,515.8% in the 3rd quarter. Brickwood Asset Management LLP now owns 1,524,074 shares of the medical instruments supplier's stock valued at $19,340,000 after purchasing an additional 1,496,935 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in DENTSPLY SIRONA by 4.1% in the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier's stock worth $279,263,000 after purchasing an additional 869,566 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也增加或减少了在 XRAY 的持股。AQR Capital Management LLC 在第二季度将其在 DENTSPLY SIRONA 的持股增加了 109.8%。AQR Capital Management LLC 目前持有 13,316,771 股这家医疗器械供应商的股票，价值 211,470,000 美元，此前在上个季度购买了额外的 6,970,086 股。挪威银行在第二季度收购了 DENTSPLY SIRONA 的新股份，价值约 39,700,000 美元。高盛集团在第一季度将其在 DENTSPLY SIRONA 的持股增加了 827.3%。高盛集团目前持有 2,434,925 股这家医疗器械供应商的股票，价值 36,378,000 美元，此前在上个季度购买了额外的 2,172,343 股。Brickwood Asset Management LLP 在第三季度将其在 DENTSPLY SIRONA 的持股增加了 5,515.8%。Brickwood Asset Management LLP 目前持有 1,524,074 股这家医疗器械供应商的股票，价值 19,340,000 美元，此前在上个季度购买了额外的 1,496,935 股。最后，先锋集团在第三季度将其在 DENTSPLY SIRONA 的持股增加了 4.1%。先锋集团目前持有 22,006,576 股这家医疗器械供应商的股票，价值 279,263,000 美元，此前在此期间购买了额外的 869,566 股。95.70% 的股票由对冲基金和其他机构投资者持有。</p>
</div><p>Get <strong>DENTSPLY SIRONA</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>DENTSPLY SIRONA</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of analysts have recently commented on XRAY shares. Barclays began coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They issued an &#34;underweight&#34; rating and a $12.00 price objective for the company. Mizuho boosted their price target on shares of DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a &#34;neutral&#34; rating in a report on Monday. Bank of America raised shares of DENTSPLY SIRONA from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and increased their price objective for the company from $13.00 to $17.00 in a report on Thursday, February 19th. Zacks Research raised shares of DENTSPLY SIRONA from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Monday. Finally, UBS Group reduced their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, February 3rd. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, DENTSPLY SIRONA has an average rating of &#34;Hold&#34; and an average target price of $14.42.</p>
<div class="lb-trans"><p>一些分析师最近对 XRAY 股票发表了评论。巴克莱在 12 月 8 日的研究报告中开始覆盖 DENTSPLY SIRONA。他们给予该公司的 &#34;减持&#34; 评级，目标价为 12.00 美元。瑞穗证券在周一将 DENTSPLY SIRONA 的目标价从 14.00 美元上调至 16.00 美元，并给予该股票 &#34;中性&#34; 评级。美国银行在 2 月 19 日的报告中将 DENTSPLY SIRONA 的评级从 &#34;中性&#34; 上调至 &#34;买入&#34;，并将其目标价从 13.00 美元上调至 17.00 美元。Zacks Research 在周一的研究报告中将 DENTSPLY SIRONA 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;。最后，瑞银集团在 2 月 3 日的研究报告中将 DENTSPLY SIRONA 的目标价从 17.00 美元下调至 16.00 美元，并给予该公司 &#34;买入&#34; 评级。三位研究分析师对该股票给予了买入评级，十位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，DENTSPLY SIRONA 的平均评级为 &#34;持有&#34;，平均目标价为 14.42 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on XRAY</strong></p>
<div class="lb-trans"><p><strong>查看我们对 XRAY 的最新分析</strong></p>
</div><h2>Insider Transactions at DENTSPLY SIRONA</h2>
<div class="lb-trans"><h2>DENTSPLY SIRONA 的内部交易</h2>
</div><p>In related news, Director Gregory T. Lucier sold 82,200 shares of the firm's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website. Insiders own 0.52% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Gregory T. Lucier 在 12 月 8 日的交易中出售了 82,200 股该公司的股票。该股票以平均价格 11.14 美元出售，总交易额为 915,708.00 美元。此次出售在向证券交易委员会的法律文件中披露，该文件可通过 SEC 网站获取。内部人士持有该公司 0.52% 的股票。</p>
</div><h2>DENTSPLY SIRONA Stock Performance</h2>
<div class="lb-trans"><h2>DENTSPLY SIRONA 股票表现</h2>
</div><p>Shares of DENTSPLY SIRONA stock opened at $13.30 on Wednesday. The firm has a market cap of $2.66 billion, a PE ratio of -4.43, a price-to-earnings-growth ratio of 1.68 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $17.18. The business's fifty day simple moving average is $12.52 and its 200-day simple moving average is $12.47.</p>
<div class="lb-trans"><p>DENTSPLY SIRONA 股票在周三开盘价为 13.30 美元。该公司的市值为 26.6 亿美元，市盈率为 -4.43，市盈增长比率为 1.68，贝塔值为 0.97。该公司的速动比率为 1.03，流动比率为 1.51，债务股本比率为 1.50。DENTSPLY SIRONA Inc. 的 52 周低点为 9.85 美元，52 周高点为 17.18 美元。该公司的 50 日简单移动平均线为 12.52 美元，200 日简单移动平均线为 12.47 美元。</p>
</div><p>DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last announced its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $961.00 million for the quarter, compared to analysts' expectations of $926.40 million. During the same period last year, the business earned $0.26 EPS. The company's quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current year.</p>
<div class="lb-trans"><p>DENTSPLY SIRONA (NASDAQ:XRAY - 获取免费报告) 最近在 2 月 26 日宣布了其财报。这家医疗器械供应商报告本季度每股收益为 0.27 美元，低于市场共识预期的 0.28 美元（差额为 0.01 美元）。DENTSPLY SIRONA 的股本回报率为 18.85%，净利润率为 -16.25%。该公司本季度的收入为 9.61 亿美元，而分析师预期为 9.264 亿美元。去年同期，该公司的每股收益为 0.26 美元。该公司的季度收入较去年同期增长了 6.2%。DENTSPLY SIRONA 已将其 2026 财年的指导目标设定为每股收益 1.400-1.500 美元。股票分析师预测 DENTSPLY SIRONA Inc. 今年的每股收益将达到 1.84 美元。</p>
</div><h2>DENTSPLY SIRONA Announces Dividend</h2>
<div class="lb-trans"><h2>DENTSPLY SIRONA 宣布分红</h2>
</div><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA's payout ratio is currently -21.33%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度分红，已于 1 月 9 日（星期五）支付。12 月 26 日的登记投资者获得了 0.16 美元的分红。这代表着每年 0.64 美元的分红和 4.8% 的分红收益率。除息日为 12 月 26 日。DENTSPLY SIRONA 目前的派息比率为 -21.33%。</p>
</div><h2>Key Stories Impacting DENTSPLY SIRONA</h2>
<div class="lb-trans"><h2>影响 DENTSPLY SIRONA 的关键故事</h2>
</div><p>Here are the key news stories impacting DENTSPLY SIRONA this week:</p>
<div class="lb-trans"><p>以下是本周影响 DENTSPLY SIRONA 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Director buying: Gregory T. Lucier purchased 22,445 shares on March 3 (~$14.03) after buying 27,555 shares on March 2 (~$14.24), bringing his reported holdings to ~50,000 shares — a strong insider vote of confidence that often supports the share price. Director purchase - InsiderTrades</li>
<li>Positive Sentiment: Barrington Research raised its price target to $17 and maintained an &#34;outperform&#34; rating — a meaningful upside call relative to current levels that can attract buying interest. Barrington Research PT Raise</li>
<li>Positive Sentiment: Zacks upgraded XRAY from &#34;strong sell&#34; to &#34;hold,&#34; removing a strong negative label and supporting improved market sentiment. Zacks upgrade</li>
<li>Neutral Sentiment: Mizuho lifted its price target to $16 but kept a &#34;neutral&#34; rating — a PT boost that helps sentiment but the unchanged rating tempers immediate buying pressure. Mizuho PT Update</li>
<li>Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference on March 10 — a potential near‑term catalyst if management provides incremental guidance or color. Conference Notice</li>
<li>Neutral Sentiment: Short‑interest data in recent reports appears anomalous (reports show zero / NaN changes) — treat those short‑interest updates as reporting noise rather than a real short‑squeeze signal.</li>
<li>Negative Sentiment: Recent fundamentals still show friction: Q4 report (Feb. 26) included a slight EPS miss ($0.27 vs. $0.28) and a negative net margin, reminders that profitability and margin recovery remain key risks for longer‑term upside. MarketBeat XRAY summary</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：董事买入：Gregory T. Lucier 于 3 月 3 日购买了 22,445 股（约 $14.03），在 3 月 2 日购买了 27,555 股（约 $14.24），使其报告持股增至约 50,000 股——这是一种强烈的内部信心投票，通常会支持股价。董事购买 - InsiderTrades</li>
<li>积极情绪：Barrington Research 将其目标价上调至 $17，并维持 &#34;跑赢大盘&#34; 的评级——相对于当前水平的显著上行预期，可能吸引买入兴趣。Barrington Research 目标价上调</li>
<li>积极情绪：Zacks 将 XRAY 的评级从 &#34;强烈卖出&#34; 上调至 &#34;持有&#34;，去除了强烈的负面标签，支持市场情绪改善。Zacks 上调</li>
<li>中性情绪：瑞穗将其目标价上调至 $16，但维持 &#34;中性&#34; 评级——这一目标价的提升有助于情绪，但不变的评级抑制了短期买入压力。瑞穗目标价更新</li>
<li>中性情绪：投资者接入：管理层将在 3 月 10 日的 Leerink Partners 全球医疗会议上进行演讲——如果管理层提供增量指导或信息，这可能成为短期催化剂。会议通知</li>
<li>中性情绪：近期报告中的空头头寸数据似乎异常（报告显示零 / NaN 变化）——将这些空头头寸更新视为报告噪音，而非真实的空头挤压信号。</li>
<li>消极情绪：近期基本面仍显示出摩擦：第四季度报告（2 月 26 日）包括轻微的每股收益失误（$0.27 对 $0.28）和负净利润率，提醒我们盈利能力和利润率恢复仍然是长期上行的关键风险。MarketBeat XRAY 摘要</li>
</ul>
</div><h2>DENTSPLY SIRONA Profile</h2>
<div class="lb-trans"><h2>DENTSPLY SIRONA 概况</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.</p>
<div class="lb-trans"><p>Dentsply Sirona Inc NASDAQ: XRAY 是一家领先的全球专业牙科产品和技术制造商。该公司于 2016 年 2 月通过 Dentsply International 和 Sirona Dental Systems 的合并成立，汇聚了在牙科护理领域的悠久创新传统。总部位于北卡罗来纳州夏洛特，Dentsply Sirona 开发和销售全面的牙科耗材、实验室产品以及先进的成像和 CAD/CAM 系统。</p>
</div><p>The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.</p>
<div class="lb-trans"><p>公司的产品组合涵盖预防性、修复性、正畸、根管治疗和外科护理。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than DENTSPLY SIRONA</li>
<li>New Copper-Rich “Kraken” Zone Discovered</li>
<li>America’s 1776 happening again</li>
<li>3 Signs You May Want to Switch Financial Advisors</li>
<li>Silver's squeeze is tightening - opportunity forming</li>
<li>Trump's NEW Executive Order - BIG Changes Coming to Retirement Accounts</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 DENTSPLY SIRONA</li>
<li>新发现的富铜 &#34;克拉肯&#34; 区域</li>
<li>美国的 1776 再次上演</li>
<li>你可能想更换财务顾问的 3 个迹象</li>
<li>白银的挤压正在收紧 - 机会正在形成</li>
<li>特朗普的新行政命令 - 退休账户即将发生重大变化</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding XRAY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 XRAY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 DENTSPLY SIRONA Inc.（NASDAQ:XRAY - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WFJBWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=XRAY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in DENTSPLY SIRONA Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 DENTSPLY SIRONA 吗？</h2>
</div><p>Before you consider DENTSPLY SIRONA, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 DENTSPLY SIRONA 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DENTSPLY SIRONA wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 DENTSPLY SIRONA 并不在名单上。</p>
</div><p>While DENTSPLY SIRONA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 DENTSPLY SIRONA 目前在分析师中获得 &#34;持有&#34; 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Skba Capital Management LLC 收购了登士柏西诺德公司 $XRAY 的股份